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Hepatic arginase 2 (Arg2) is sufﬁcient to convey
the therapeutic metabolic effects of fasting
Yiming Zhang1, Cassandra B. Higgins1, Hannah M. Fortune1, Phillip Chen1, Alicyn I. Stothard2,
Allyson L. Mayer 1, Benjamin M. Swarts2 & Brian J. DeBosch1,3
Caloric restriction and intermittent fasting are emerging therapeutic strategies against obe-
sity, insulin resistance and their complications. However, the effectors that drive this
response are not completely deﬁned. Here we identify arginase 2 (Arg2) as a fasting-induced
hepatocyte factor that protects against hepatic and peripheral fat accumulation, hepatic
inﬂammatory responses, and insulin and glucose intolerance in obese murine models. Arg2 is
upregulated in fasting conditions and upon treatment with the hepatocyte glucose trans-
porter inhibitor trehalose. Hepatocyte-speciﬁc Arg2 overexpression enhances basal ther-
mogenesis, and protects from weight gain, insulin resistance, glucose intolerance, hepatic
steatosis and hepatic inﬂammation in diabetic mouse models. Arg2 suppresses expression of
the regulator of G-protein signalling (RGS) 16, and genetic RGS16 reconstitution reverses the
effects of Arg2 overexpression. We conclude that hepatocyte Arg2 is a critical effector of the
hepatic glucose fasting response and deﬁne a therapeutic target to mitigate the complications
of obesity and non-alcoholic fatty liver disease.
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Obesigenic cardiometabolic disease arises from a con-stellation of environmental, genetic and meta- and epi-genetic factors1. Clinically, intensive lifestyle
management remains the primary means of treating obesity and
its comorbidities, including insulin resistance, non-alcoholic fatty
liver disease (NAFLD), and thermic depression. Intensive lifestyle
management encompasses a wide range of interventions, such as
increased locomotion, selective macronutrient elimination (e.g.,
ketogenic diets), intermittent fasting (IF), and caloric restriction
(CR)2. Although lifestyle measures effectively treat obesity,
insulin resistance and NAFLD2–8, caloric restriction, fasting and
extreme dietary alterations are often unsustainable, unpalatable,
and are in some cases associated with clinical complications9–11.
At the nexus of portal and systemic circulations, the hepatocyte
coordinates peripheral responses to changes in nutrient ﬂux.
During physiological fasting, the hepatocyte provides glucose and
ketones as fuel for fasting peripheral organs. In addition,
hepatocyte-derived endocrine signals, such as ﬁbroblast growth
factor 21 (FGF21), enhance peripheral insulin sensitivity and
promote basal thermogenesis. These adaptations ostensibly
maintain thermic equilibrium during prolonged fasting and
hibernation, and maximize post-fasting nutrient absorption12–16.
The physiological fasting response is itself induced by several key
transcriptional regulators that are also activated during fasting:
peroxisome proliferator activated receptor α (PPARα), PPARγ
coactivator 1α (PGC1α), SIRT117,18, and transcription factor EB
(TFEB)19–23. However, surprisingly little is known regarding
hepatocyte-intrinsic factors that regulate hepatic and extrahepatic
responses to fasting.
We recently demonstrated that hepatic glucose transport
blockade is sufﬁcient to confer or augment the adaptive metabolic
changes associated with generalized caloric restriction and
intermittent fasting24–29. Germline deletion of the hepatic glucose
transporter (GLUT) 8 increased hepatocyte fatty acid oxidation
and decreased fructose-induced de novo lipogenesis in isolated
hepatocytes25. In vivo, targeted GLUT8 disruption increased
basal thermogenesis25,27,28, protected from diet-induced NAFLD
and insulin resistance, and augmented canonical hepatic fasting
responses (e.g., PPARα and FGF2125,27,28). Similarly, pharma-
cological hepatic GLUT inhibition by the GLUT inhibitor, tre-
halose, activated hepatocyte fasting responses—autophagic ﬂux
and FGF21 secretion—that was dependent on hepatocyte
TFEB24,30,31. The hepatic response to pharmacological hepatic
GLUT inhibition is to activate thermogenesis, and reduce hepatic
steatosis and insulin resistance24,26,30,32. The full mechanisms
driving the hepatocyte glucose fasting response and the utility of
these responses against cardiometabolic disease, however, are
only now being elucidated.
Here, we identify the arginine metabolizing enzyme, arginase 2
(Arg2) as a hepatocyte glucose fasting-induced factor that is
sufﬁcient to convey the adaptive hepatic and peripheral metabolic
changes induced during CR and IF. Hepatocyte Arg2 mRNA and
protein expression is induced during acute and prolonged fasting,
and after treatment with the hepatic GLUT inhibitor, trehalose.
Hepatocyte-speciﬁc Arg2 overexpression increases basal ther-
mogenesis, enhances insulin sensitivity, and decreases hepatic
steatosis and inﬂammation in genetic and diet-induced models of
diabetes and NAFLD. Unbiased transcriptomic analysis identiﬁes
the regulator of G-protein-coupled receptor signaling (RGS) 16 to
be among the most highly suppressed hepatic genes in Arg2-
overexpressing db/db diabetic mice. Moreover, hepatocyte-
speciﬁc genetic RGS16 reconstitution in the context of Arg2
overexpression reverses the hepatic and peripheral therapeutic
effects of Arg2 overexpression. We conclude that Arg2 represents
an effector of the hepatocyte-intrinsic fasting response that
modulates hepatic and extrahepatic metabolic homeostasis, and
that the trehalose class of disaccharide GLUT inhibitors activates
this pathway. More broadly, this study identiﬁes a seminal link
between hepatic Arg2 and G-protein signaling in the pathogenesis
of metabolic disease.
Results
Arg2 is induced during fasting and pseudo-fasting. We pre-
viously demonstrated that glucose transporter inhibition by the
hepatic GLUT inhibitor, trehalose, enhances peripheral thermo-
genesis, and mitigates hepatic steatosis by inducing hepatocyte
fasting-like pathways24,26,29. RNA-seq analysis of trehalose-
treated primary hepatocytes identiﬁed hepatocyte arginase 2
(Arg2) to be among the most highly upregulated genes relative to
untreated hepatocytes. We conﬁrmed these data by quantitative
real-time RT-PCR (qPCR) and immunoblot analysis, demon-
strating rapid, dose-dependent, cell autonomous Arg2 induction
within 24 h post trehalose (1 mM, 10 mM, and 100 mM) treat-
ment (Fig. 1a). This Arg2 response was energy deﬁcit-dependent,
as indicated by pre-treating cells with pyruvate as an energy
substrate to bypass the GLUTs targeted by 100 mM trehalose.
Pyruvate signiﬁcantly reduced the trehalose-induced Arg2
response to trehalose (Fig. 1b). Because trehalose catabolism by
host (brush border, hepatocyte, or renal) or microbiotic trehalases
can theoretically reduce the bioavailability of orally administered
trehalose therapy, we compared the potency of native trehalose
with that of a trehalase-resistant analog, lactotrehalose32–34, to
induce Arg2 expression in vitro (Fig. 1c). Lactotrehalose-induced
Arg2 expression indeed was signiﬁcantly enhanced at 10 mM and
100 mM when compared with native trehalose at equivalent doses
(Fig. 1c). Trehalose similarly induced Arg2 mRNA and protein in
livers from mice fed 3% trehalose water (5 days) ad libitum
in vivo (Fig. 1d, and Supplementary Fig. 6). The similarities
between trehalose-induced pseudo-fasting responses in the liver
and physiological macronutrient withdrawal prompted us to
quantify the Arg2 response in livers from mice fasting up to 24 h.
qPCR and immunoblot analysis identiﬁed Arg2 to be activated
during physiological fasting (Fig. 1e, and Supplementary Fig. 6).
Arg2 upregulation during fasting is cell-intrinsic, as determined
by subjecting isolated primary murine hepatocytes to serum and
glucose deprivation (24 h), after which Arg2 mRNA expression
was signiﬁcantly upregulated (Fig. 1f).
We demonstrated that hepatocyte glucose transport blockade
attenuates insulin resistance and hepatic steatosis in multiple
obese models24,25,27–29. To test the hypothesis that hepatocyte
Arg2 activation downstream of the fasting response is sufﬁcient
to drive these therapeutic effects, we examined the cell-intrinsic
consequences of forced Arg2 overexpression on hepatocyte
triglyceride accumulation, inﬂammatory cytokine and chemo-
kine activation, and insulin signal transduction. BSA-conjugated
fatty acid treatment (FFA) both without and with 1 nM
lipopolysaccharide (LPS) induced TG accumulation and inﬂam-
matory gene markers interleukin 1β (Il-1β), interleukin 6 (Il-6),
tumor necrosis factor α (Tnf-α), monocyte chemoattractant
protein 1 (Mcp1; also known as Ccl2), and CXC chemokine
ligand 9 (Cxcl9) in wild-type primary hepatocyte cultures
(Fig. 1g). In each condition, fat accumulation and cytokine/
chemokine expression was signiﬁcantly attenuated by Arg2
overexpression (Fig. 1g). In parallel, we veriﬁed expression of
functional protein by quantifying urea production in vitro, which
revealed an eightfold increase in urea production upon Arg2
overexpression (not shown). To deﬁne the effect of Arg2
overexpression on hepatocyte insulin sensitivity in vitro, primary
hepatocytes were transfected with β-galactosidase or Arg2,
serum-deprived overnight, then stimulated with 10 nM recom-
binant insulin. Arg2-overexpressing cultures exhibited enhanced
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insulin-induced AKT phosphorylation (Fig. 1h, and Supplemen-
tary Fig. 6). Together, these data suggested that Arg2 over-
expression cell autonomously mitigates hepatocyte fat
accumulation, LPS-stimulated inﬂammatory responses and
insulin sensitivity through the AKT pathway.
To deﬁne whether suppression of Arg2 correlates with
metabolic disease, we compared hepatocyte Arg2 expression in
fructose-treated and untreated primary hepatocyte cultures, and
in LepR heterozygous (db/+) mice with LepR-deﬁcient (db/db)
diabetic mice, and in mice fed with a high-fat, high-sucrose diet
(HFHS, 14 weeks). This revealed signiﬁcantly reduced Arg2
expression in db/db mice and in response to fructose treatment
(Fig. 1i). Therefore, Arg2 is induced during fasting and is reduced
in states of nutritional excess.
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Fig. 1 Arg2 is upregulated during fasting and trehalose treatment. a Arg2 gene expression by qPCR analysis of cultured primary hepatocytes treated with
1–100mM trehalose (n= 6 cultures per group, derived from three mice). b Arg2 gene expression in response to 100mM trehalose in the presence or
absence of energetic reconstitution with pyruvate in primary hepatocytes (n= 6 hepatocyte cultures per group, derived from three mice). c Arg2 gene
expression by qPCR analysis of cultured primary hepatocytes treated with trehalose, or the trehalase-resistant analog, lactotrehalose (n= 6 cultures per
group, derived from three mice). d Hepatic Arg2 expression by qPCR (top) and immunoblot (bottom) analysis of crude liver lysates from mice subjected to
trehalose feeding (3% water ad libitum, 5 days) (n= 5 mice per group). e Arg2 expression by qPCR and immunoblot analysis of crude liver lysates from
mice subjected to fasting (n= 5 mice per group). f Arg2 expression by qPCR analysis of primary hepatocytes subjected to low glucose and low serum
treatment (24 h). g Left panels: in vitro enzymatic-colorimetric triglyceride accumulation assay and Right: Arg2 gene expression in response to BSA-
conjugated fatty acids with or without 1 nM lipopolysaccharide (LPS) and with or without adenoviral Arg2 overexpression in primary hepatocytes. Below:
Inﬂammatory gene marker expression in parallel hepatocyte cultures analyzed above (n= 6 cultures per group, derived from three mice). h Immunoblot
analysis of AKT phosphorylation in AML12 hepatocytes treated with or without 10 nM insulin following overnight serum deprivation (n= 6 cultures per
group). i Arg2 gene expression in primary hepatocyte cultures following 24 h treatment with 10mM fructose, or in crude liver lysates from db/+mice or
db/db diabetic mice (n= 4 mice per group). For box plots, the midline represents the median, boxes represent the interquartile range and whiskers show
the full range of values. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to bracketed control, by two-tailed Student’s t-test
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Liver Arg2 blocks hepatic steatosis and insulin resistance.
Forced Arg2 expression in vitro reduced steatosis and enhanced
insulin signaling. In vivo, hepatocyte-speciﬁc Arg2 over-
expression was achieved by delivering adeno-associated virus 8 by
tail-vein injection in mice (hereafter, AAV8-Arg2 mice). We fed
these mice either a normal chow diet (NCD) or a 5-week high-
fructose diet (HFrD, experimental design in Fig. 2a) to test
whether forced Arg2 expression in vivo also enhances insulin
signaling and reduces hepatic steatosis. We ﬁrst demonstrated
restricted hepatic overexpression of the Arg2 construct by qPCR
and western blot analysis, without upregulation in skeletal muscle
or brown adipose tissue (Supplementary Fig. 1a). Importantly, we
did not observe changes in hepatic Arg1 mRNA expression in
hepatic Arg2-overexpressing mice (Supplementary Fig. 1a).
Hepatic Arg2 overexpression signiﬁcantly increased lean mass
and reduced fat mass in NCD and HFrD-fed mice (Fig. 2b, c).
Moreover, Arg2 attenuated HFrD-induced weight gain without
altering food intake (Supplementary Fig. 1b). Accordingly,
indirect calorimetry revealed enhanced basal thermogenesis and
oxygen and carbon dioxide exchange in AAV8-Arg2 versus
HFrD-fed AAV8-controls (Fig. 2d), without altering light- or
dark-cycle movement (Supplementary Fig. 1c).
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Fig. 2 Hepatic Arg2 improves whole-body metabolism and insulin sensitivity. a Experimental design to test the role of Arg2 in protection from HFrD
feeding. b, c Body weight (b) and echoMRI analysis of body composition (c) of AAV8-Control or AAV8-Arg2 WT mice fed NCD (n= 6–7 mice per group)
or HFrD (n= 8 mice per group). d Indirect calorimetric quantiﬁcation of VO2, VCO2, RER, and energy expenditure during light and dark cycles in AAV8-
control and -Arg2 mice fed the indicated diet (n= 6 mice for NCD groups and n= 8 mice for HFrD groups). e Serum insulin (left), serum glucose (middle),
and HOMA2 IR (right) in AAV8-control and -Arg2 mice fed NCD or HFrD. f Intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT)
(n= 5 mice per group). g Hepatic mRNA expression of insulin-responsive genes. For box plots, the midline represents the median, boxes represent the
interquartile range and whiskers show the full range of values. For bar graphs, data represent mean+s.e.m. *P < 0.05, **P < 0.01, ***P < 0.005, ****P <
0.0001 relative to vehicle treatment, by two-tailed Student’s t-test
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The generalized fasting response induces peripheral lipolysis to
generate substrate for liver fatty acid oxidation and ketogenesis.
Analogously, hepatic Arg2 overexpression increased serum-free
fatty acid (FFA) in AAV8-Arg2 HFrD mice with no signiﬁcant
changes in serum triglyceride (TG), total cholesterol, and LDL-C
(Supplementary Fig. 1d). AAV8-Arg2 mice exhibited lower serum
insulin and glucose concentrations in both NCD-fed and HFrD-
fed group which resulted in lower HOMA of insulin resistance
(HOMA-IR) (Fig. 2e). Glucose tolerance test (GTT) and insulin
tolerance testing (ITT) conﬁrmed improved glucose tolerance and
insulin sensitivity secondary to hepatic Arg2 overexpression in
HFrD-fed mice (Fig. 2f), without effects on glucose or insulin
tolerance in NCD-fed mice (Supplementary Fig. 1e). With regard
to insulin-responsive gene activation, Arg2 signiﬁcantly increased
expression of insulin receptor substrate 1 (Irs1), insulin-like
growth factor binding protein 1 (Igfbp1), and argininosuccinate
synthase 1 (Ass1). With regard to genes involved in de novo
lipogenesis, only monoacylglycerol O-acyltransferase 1 (Mogat1)
(Fig. 2g) was reduced in AAV8-Arg2 mice.
Hepatic analysis revealed lower liver weight and liver weight-
to-body-weight ratios in HFrD-fed AAV8-Arg2 mice when
compared with HFrD-fed AAV8-Controls, whereas no changes
were detected between NCD-fed AAV8-Arg2 and AAV8-control
groups (Supplementary Fig. 1f). Histological analysis of livers
from control and AAV8-Arg2 mice by H&E and Oil Red O
staining demonstrated that Arg2 attenuated HFrD-induced
hepatic lipid accumulation (Fig. 3a). These ﬁndings were
conﬁrmed by signiﬁcantly reduced quantitative intrahepatic
triglycerides, cholesterol and low-density lipoprotein cholesterol
without changes in hepatic free fatty acids (FFA) (Fig. 3b).
Although we observed no changes in serum ALT, AST or
albumin in any group (Supplementary Fig. 1g), hepatic
inﬂammatory gene expression (e.g., Il-1β, Il-6, Tnfα, Ccl2, Cxcl9)
was signiﬁcantly lower in the livers of AAV8-Arg2 mice when
compared with AAV8-Controls in response to HFrD (Fig. 3c).
Analysis of major metabolic pathways yielded no consistent
changes in de novo lipogenic genes, import export (Cd36/FAT,
Mttp), or fatty acid oxidation (Acox1, Cpt1α, Cpt1β, Ucp2, Pparα,
Pgc1α, Fgf21) in HFrD-fed AAV8-Arg2 mice relative to littermate
AAV8-Controls (Supplementary Fig. 1h–j).
Hepatic Arg2 enhances thermogenesis in db/db diabetic mice.
To address the generalizability of the protective effects of hepatic
Arg2, we explored the effects of Arg2 expression in a genetic
model of obesity, leptin receptor-deﬁcient (db/db) diabetic mice
(Experimental outline in Fig. 4a). qPCR and immunoblot analysis
conﬁrmed restricted Arg2 overexpression in liver without Arg2
overexpression in visceral white adipose, brown adipose or ske-
letal muscle tissue (Supplementary Fig. 2a, b). Hepatic Arg1
mRNA was increased by 10% uniquely in this genetically obese
model (but not in the HFrD model), whereas hepatic Arg2
increased greater than 20-fold in db/db AAV8-Arg2 mice (Sup-
plementary Fig. 2a). Hepatic Arg2 overexpression attenuated
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body weight gain in db/db AAV8-Arg2 mice compared with the
db/db AAV8-Control mice (Fig. 4b) without changes in total food
intake or locomotion (Supplementary Fig. 2c, d). Accordingly, db/
db Arg2 mice had greater lean mass and lower fat mass (Fig. 4c),
which corresponded with signiﬁcantly higher VO2, VCO2, and
energy expenditure in db/db AAV8-Arg2 mice versus db/db
AAV8-Arg2 control mice. We did not observe changes in
food consumption or movement (Fig. 4d, and Supplementary
Fig. 2c, d). Hepatic Arg2 overexpression also increased circulating
TG, decreased total cholesterol and LDL-C, but it did not change
FFA (Supplementary Fig. 2e). Analysis of insulin and glucose
homeostasis revealed that serum insulin and homeostatic model
assessment of insulin resistance (HOMA2-IR) were signiﬁcantly
decreased in db/db AAV8-Arg2 mice (Fig. 4e). Similarly, AAV8-
Arg2-treated db/db mice exhibited signiﬁcantly improved insulin
tolerance testing (ITT) and trends toward improved glucose tol-
erance when compared with AAV8-Control injected db/db lit-
termates (Fig. 4f). Consistent with these physiological ﬁndings,
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gene expression of insulin-responsive genes, Irs1, Igfbp1, and
Ass1, were elevated in livers of db/db AAV8-Arg2 mice versus
AA8-Controls (Fig. 4g). db/db AAV8-Arg2 mice exhibited sig-
niﬁcantly enhanced hepatic AKT phosphorylation relative to db/
db AAV8-Control littermates (Fig. 4h, and Supplementary Fig. 7).
Similarly, analysis of iBAT, skeletal muscle and visceral adipose
tissues each revealed trends toward increased AKT phosphor-
ylation in db/db AAV8-Arg2 mice relative to db/db AAV8-
Control littermates (Supplementary Fig. 2f).
Hepatic Arg2 mitigates hepatic steatosis in db/db mice. We
examined the role of Arg2 in mediating the major hallmarks of
hepatic steatosis and inﬂammation. Similar to the observations
made in HFrD-fed AAV8-Arg2 mice, hepatic Arg2 over-
expression decreased hepatic TG, FFA, and LDL-C content,
without signiﬁcantly altering total hepatic cholesterol in db/db
AAV8-Arg2 mice (Fig. 5a). Histological analysis of H&E and Oil
Red O staining conﬁrmed reduced lipid accumulation in db/db
AAV8-Arg2 mice when compared with AAV8-control littermates
(Fig. 5b). Biochemically, we observed lower serum ALT and
trends toward lower AST with elevated serum albumin con-
centration in db/db AAV8-Arg2 mice relative to those db/db
AAV8-Control mice (Fig. 5c). Attenuated steatosis in db/db
AAV8-Arg2 mice was paralleled by decreased fatty acid synthetic
genes (Fig. 5d), and fatty acid uptake and export genes (Fig. 5e).
However, no consistent changes in gluconeogenic or fatty acid
oxidation gene programs were observed (Supplementary Fig. 2g).
Arg2 overexpression also attenuated the hepatic inﬂammatory
gene expression response, as assessed by qPCR analysis of Il-1β,
Il-6, Tnf-α, Ccl2, and Cxcl9 in db/db mice as compared with their
littermate controls at 10 weeks of age (Fig. 5f). Moreover, in
hepatic tissue extracts and in serum, only hepatic alanine was
signiﬁcantly altered in db/db AAV8-Arg2 mice versus db/db
a
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AAV8-Control mice after multiple comparison correction, as
quantiﬁed by targeted metabolomic analysis (Supplementary
Table 1). Surprisingly, no signiﬁcant steady-state changes in urea
cycle intermediaries or in arginine itself were deﬁned in serum or
hepatic extracts from db/db AAV8-Control and db/db AAV8-
Arg2 mice.
Higher cholesterol and insulin in Arg2ASO db/db mice.
Hepatic Arg2 overexpression protected mice from diet- and
genetically-induced insulin resistance, adiposity and hepatic
steatosis and inﬂammation. To examine the consequences of
liver-selective Arg2 deﬁciency, we treated db/db mice with either
scrambled or Arg2-directed antisense oligonucleotides, followed
by metabolic assessment (Fig. 6a). This resulted in signiﬁcant
hepatic Arg2 mRNA knockdown without knockdown in iBAT,
SKM or WAT (Supplementary Fig. 3a) or in kidney (not shown).
There were no hepatic changes in Arg1 mRNA expression
(Supplementary Fig. 3a). Endpoint total body weight, total fat
mass, and fat percentage did not signiﬁcantly change (Fig. 6b),
although food consumption was slightly lower in liver Arg2-
deﬁcient mice (Supplementary Fig. 3b), and core temperature was
lower in db/db Arg2 ASO-treated mice when compared with
db/db Control ASO-treated mice (Fig. 6c).
Quantifying serum parameters in db/db Arg2 ASO-treated
mice revealed lower serum triglycerides and glucose, but elevated
total cholesterol and LDL cholesterol as well as elevated insulin
and calculated HOMA2 in db/db Arg2 ASO-treated mice when
compared with db/db Control ASO-treated mice (Fig. 6d, and
Supplementary Fig. 3c), although fasting glucose was lower in
Arg2 ASO mice, in concordance with lower gluconeogenic gene
(G6pc and Fbp1) expression (Fig. 6d, and Supplementary Fig. 3d).
Total areas under the insulin- and glucose tolerance testing curves
were unchanged in db/db Control versus Arg2 ASO-treated mice
(Fig. 6e).
Liver steatosis and inﬂammation after liver Arg2 knockdown.
We next examined hepatic effects of liver Arg2 deﬁciency in
db/db mice. Total liver weight and liver weight-to-body weight
ratios were elevated in liver Arg2-deﬁcient mice (Fig. 7a). Con-
comitantly, liver Arg2-deﬁcient db/db mice exhibited increased
neutral lipid accumulation, as determined by routine histological
and Oil Red O analyses (Fig. 7b). Accordingly, hepatic
a
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triglycerides, total cholesterol and LDL-C and serum ALT and
AST were all increased (Fig. 7c), without alterations in hepatic
synthetic function in liver Arg2-deﬁcient mice versus db/db
controls (Fig. 7d). Hepatic inﬂammatory marker gene expression
of Il-6, Tnf-α, Ccl2, and Cxcl9 was increased in hepatic Arg2-
deﬁcient db/db mice versus db/db controls (Fig. 7e). Whereas
gluconeogenic gene expression in Arg2-deﬁcient db/db livers
(Supplementary Fig. 3d), genes involved in de novo lipogenesis:
Scd1, Gpam, and Pparγ were elevated in Arg2-deﬁcient db/db
livers when compared with db/db controls.
Transcriptomics reveal inverse Arg2-Rgs16 regulation. To
explore potential mechanisms by which hepatic Arg2 over-
expression improves hepatic lipid homeostasis, inﬂammation and
insulin sensitivity, we examined unbiased transcriptional proﬁling
by RNA-seq to analyze transcriptomic changes in the livers of
db/db AAV8-Arg2 mice and AAV8-Control mice. Principal
component analyses revealed distinct gene clusters between db/db
and db/db AAV8-Arg2 groups (Fig. 8a). This was corroborated by
unsupervised gene-level clustering revealing distinctive patterns
of signiﬁcantly upregulated and downregulated genes when
comparing db/db AAV8-Arg2 and db/db AAV8-Control mice
(Fig. 8b). Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis of differentially expressed genes
revealed enhanced phosphatidylinositol signaling, mTOR and
FOXO signaling, consistent with enhanced hepatic insulin sig-
naling. Conversely, consistent with fasting-state cellular physiol-
ogy, signiﬁcant downregulation of fructose, mannose, amino acid
and nucleotide sugar metabolism, fatty acid elongation and bio-
synthesis, and carbon/pyruvate metabolism (Fig. 8c). Volcano
plot analysis conﬁrmed upregulation of Arg2 gene expression in
db/db AAV8-Arg2 mice, and identiﬁed the hepatocyte regulator
of G-protein signaling 16 (RGS16) as among the most highly
suppressed genes in db/db AAV8-Arg2 mice (Fig. 8d). In light of
the described pathogenic role of RGS16 in hepatic steatosis35, we
a
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further interrogated whether Arg2 and RGS16 anti-correlate in
multiple models of metabolic disease. In db/+ mice, in wild-type
mice overexpressing Arg2 and in db/db AAV8-Arg2 mice, we
observed an inverse relationship between Arg2 and Rgs16
expression (Fig. 8e). Moreover, hepatic Rgs16 mRNA and protein
levels were signiﬁcantly suppressed by direct Arg2 expression in
the livers of chow and HFrD-fed and db/db AAV8-Arg2 mice
(Fig. 8f, g, and Supplementary Fig. 8), whereas hepatic Arg2-
deﬁcient mice exhibited upregulated hepatic Rgs16 mRNA
(Supplementary Fig. 4). Together, the data identify an inverse
relationship between hepatic Rgs16 and Arg2.
Hepatic Rgs16 reconstitution reverses hepatic Arg2 effects. We
next examined the hypothesis that genetic reconstitution of
hepatic RGS16 in the context of Arg2 overexpression would
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reverse the improvements in hepatic steatosis, inﬂammation and
insulin and glucose intolerance observed in Arg2-treated db/db
mice. To that end, we treated db/db AAV8-Control and AAV8-
Arg2 mice with adenovirus encoding GFP (Ad-Control) or RGS16
(Ad-Rgs16, Experimental outline, Fig. 9a). We conﬁrmed Arg2
overexpression, Rgs16 suppression and mild Rgs16 reconstitution
in response to our AAV8 and adenoviral manipulation (Supple-
mentary Fig. 5a, b). In db/db mice, Arg2 overexpression atte-
nuated weight gain, increased fat mass and decreased lean mass,
although we noted the weight bifurcation occurred later in the
adenovirus-treated cohorts (Fig. 9b) than in the control cohorts
(Fig. 4b). Nevertheless, these changes were reversed by RGS16
reconstitution in db/db AAV8-Arg2 mice when compared with
Ad-Control-treated mice (Fig. 9b, c). db/db AAV8-Arg2 mice
again exhibited enhanced energy expenditure and oxygen con-
sumption by indirect calorimetry when compared with db/db
AAV8-control mice without altering locomotion or food con-
sumption (Fig. 9d, and Supplementary Fig. 5c, d). However,
RGS16 reconstitution reversed the energetic enhancements in
db/db AAV8-Arg2 mice (Fig. 9d). Accordingly, Rgs16
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reconstitution substantially exacerbated insulin resistance in db/db
mice as deﬁned by serum insulin, glucose, and HOMA2-IR
(Fig. 9e). This was further conﬁrmed by glucose and insulin tol-
erance testing (Fig. 9f). Hepatic insulin sensitivity, as quantiﬁed by
insulin-stimulated AKT phosphorylation, was impaired by Rgs16
expression in the liver (Fig. 9g, and Supplementary Fig. 9) when
compared with db/db AAV8-Arg2 mice treated with Ad-Control.
In the liver, Arg2 decreased hepatic TG, cholesterol, FFA, and
LDL-C in db/db Arg2 mice, and these effects were signiﬁcantly
reversed upon Rgs16 reconstitution in db/db AAV8-Arg2 mice
(Fig. 10a) with no signiﬁcant changes detected in serum TG,
cholesterol, FFA and LDL-C (Supplementary Fig. 5e). Histologi-
cal analysis by H&E and Oil Red O demonstrated that Arg2
overexpression reduced hepatic lipid accumulation, which was
reversed in db/db mice also expressing AdRGS16 (Fig. 10b).
Similarly, serum ALT, AST as well as hepatic inﬂammatory
marker expression in db/db mice were each signiﬁcantly elevated
in db/db AAV8-Arg2 mice expressing Ad-Rgs16 as compared
with db/db AAV8-Arg2 Ad-Control littermates (Fig. 10c, d).
Rgs16 overexpression reversed Arg2 effects on Igfbp1 expression,
and RGS16 overexpression generally increased genes involved in
de novo lipogenesis in liver, including Chrebp, Acc1, Gpam, and
Pparγ (Fig. 10e). However, the expression of mRNAs encoding
beta oxidation and fatty acid uptake and export were largely
unchanged by hepatic Arg2 overexpression or Rgs16 reconstitu-
tion (Supplementary Fig. 5f).
Discussion
Arginases are ancient, highly conserved enzymes36,37, the purpose
of which is long considered to be conversion of L-arginine to urea
and ornithine36–43. More recently, these enzymes have been
implicated in the biosynthesis of polyamines, and in proline,
glutamate, creatine, and agmatine biosynthesis as well38,40,42,44.
The two vertebrate arginases, type I and type II evolved separately
from an early gene duplication event36, which ultimately man-
ifests as both distinct and overlapping enzymatic functions, which
yet remain to be fully appreciated42. We demonstrate here that
Arg2 is more profoundly induced during fasting in liver versus
Arg1. This opens the possibility now that the arginases regulate
fasting biology in the liver. Although the total abundance of Arg1
is much greater than that of Arg2 in the basal setting42, the data
here suggest that Arg1 and Arg2 are in fact differentially regulated
during fasting, and may thus serve divergent functions as part of
the physiological fasting response. The fundamental biological
purpose of hepatocyte Arg2 regulation during fed and fasting
states, and during health and disease remains an intriguing area
of further exploration.
The fasting response enhances hepatic and extrahepatic energy
homeostasis, and yet the intermediaries that dictate these effects
remain poorly understood. Here, we demonstrate that hepatocyte
arginase 2 is upregulated during fasting, and after trehalose and
trehalose analog treatment. Furthermore, Arg2 overexpression
per se attenuates insulin resistance, hepatic steatosis and
inﬂammation in high-fructose-fed and genetically obese models.
Arg2 is therefore a tractable target that can be used to leverage the
therapeutic hepatic fasting response. Although it must be noted
that some of the individual metabolic improvements observed
upon AAV8-Arg2 expression were modest. For example, we
observed 20–25% improvements in glucose and insulin tolerance
in HFrD-fed AAV8-Arg2 and db/db x AAV8-Arg2 mice.
0.0
0.5
1.0
1.5
2.0
2.5 *** **
0
20
40
60
80
H
ep
at
ic
 tr
ig
lyc
er
id
es
(ug
 
m
g–
1  
tis
su
e
)
H
ep
at
ic
 
FF
A
(nm
ol
 m
g–
1  
tis
su
e
)
H
ep
a
tic
 c
ho
le
st
er
ol
(ug
 
m
g–
1  
tis
su
e
)* *
db/db AAV8-Control db/db AAV8-Arg2
db/db AAV8-Arg2 Ad-Rgs16
db/db AAV8-Arg2 Ad-Rgs16db/db AAV8-Arg2
120 200
150
50
0
100
* *
80
40
0
0
1
2
3
4
0
1
2
3
4
***
****
** **
H
ep
at
ic 
LD
L-
C
(ug
 m
g–
1  
tis
su
e)
b
AAV8-Control AAV8-Arg2
H
&E
O
il R
ed
 O
AAV8-Arg2
Ad-Rgs16
a
AS
T 
(U
 
L–
1 )
AL
T 
(U
 
L–
1 )
0
2
3
4
5
Al
bu
m
in
 (g
 dL
–
1 ) n.s.
c
Il-1

IL-
6
Tn
f-
Cc
l2
Cx
cl9
0
5
10
15
R
el
a
tiv
e
 
ex
pr
e
ss
io
n
*
***
* **
n.s.
* * *
****
n.s.
db/db AAV8-Control
db/db AAV8-Arg2
db/db AAV8-Arg2 Ad-Rgs16
d
Irs
1
Igf
bp
1
As
s1 Gc
k
Mo
ga
t1
0
2
4
6
R
el
a
tiv
e
 
ex
pr
es
sio
n **
***
db/db AAV8-Arg2
db/db AAV8-Control
*
db/db AAV8-Arg2 Ad-Rgs16
*
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
e
Fig. 10 Hepatic RGS16 reconstitution reverses Arg2-mediated improvements in hepatic fat accumulation. a H&E and Oil Red O-stained liver sections from
db/db AAV8-Control and AAV8-Arg2 mice treated with Ad-GFP or Ad-RGS16. Scale bar, 100 µm. b Hepatic triglycerides, cholesterol, non-esteriﬁed fatty
acids and LDL-C in livers from db/db AAV8-Control and AAV8-Arg2 mice treated with Ad-GFP or Ad-RGS16. c Serum ALT, AST and albumin in db/db
AAV8-Arg2 mice expressing Ad-GFP or Ad-RGS16. d Hepatic inﬂammatory gene marker mRNA by qPCR. e mRNA expression of insulin-responsive genes
by qPCR (n= 8 mice per group). For box plots, the midline represents the median, boxes represent the interquartile range and whiskers show the full range
of values. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001; n.s., not signiﬁcant; relative to control treatment, by two-tailed Student’s t-test
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09642-8
12 NATURE COMMUNICATIONS |         (2019) 10:1587 | https://doi.org/10.1038/s41467-019-09642-8 | www.nature.com/naturecommunications
However, it should also be noted that the magnitude of changes
in glucose and insulin tolerance here mirrors that observed in
humans subjected to short-term intermittent fasting or caloric
restriction, which results in 11–30% improvements in HOMA-IR,
and 11–40% improvement in fasting plasma insulin levels7.
Indeed even high-intensity, supervised diet and exercise training
regimens over a 4-month period produced even more modest
improvements in glucose tolerance, and only for the highest-
intensity intervention groups45.
The observation that hepatic Arg2 activation is therapeutic
originated from prior observations that hepatic fasting signals
(e.g., TFEB, PPARα) mediated the therapeutic effects of genetic or
pharmacological glucose transport blockade27,29. However, the
observation that hepatic glucose uptake is impaired in diabetic
patients46 may raise an apparent paradox, in light of the intrinsic
therapeutic effect of hepatic glucose transport blockade. At least
two key differences between the fasted liver and the diabetic liver
resolve this apparent paradox. First, insulin stimulates hepatic
glucose uptake by twofold over the fasting state47. In diabetic
patients, insulin-stimulated glucose uptake is impaired (by 17.4%
in the Iozzo study46) but this degree of blunted fed-state glucose
uptake would not be expected to mimic a true hepatocyte fasting
response. Second, basal hepatic glucose uptake should remain
elevated through hepatic facilitative transporters GLUT1, GLUT2,
and GLUT8. This is because basal hyperglycemia in the diabetic
patient provides a glucose concentration gradient that drives
these facilitative transporters even in the absence of insulin-
stimulated glucose transport. This rise in basal hepatic glucose
uptake would be expected to further impede the hepatocyte
fasting response. Thus, although insulin-stimulated glucose
uptake is relatively impaired in the insulin-resistant state, our
data suggest that pharmacological hepatic GLUT blockade or
targeted hepatic Arg2 activation can drive the therapeutic hepatic
glucose response in diet-induced and genetic models of obesity
and insulin resistance.
Taken further in context, Arg2 appears to serve tissue-speciﬁc,
and context-dependent functions in energy homeostasis. These
context-dependent functions underscore the importance of
leveraging hepatocyte fasting responses over less targeted
approaches to metabolic therapy. Endothelial Arg2 over-
expression surprisingly impaired endothelial cell autophagy and
AMPK signaling48, and macrophage Arg2 appears to have pro-
inﬂammatory functions49–51, whereas germline Arg2 deletion
effects are not yet clear49,52. The clinical implications of these
data should thus be underscored, especially in view of recent
momentum to inhibit arginases in the setting of cardiovascular
and other disease53. Our liver-deﬁcient Arg2 model suggests that
blocking Arg2 without sufﬁcient speciﬁcity may have negative
metabolic consequences, particularly if hepatic Arg2 is inad-
vertently targeted. Here, we utilized a targeted, hepatocyte-
speciﬁc overexpression approach to demonstrate further adaptive
metabolic effects of hepatic Arg2 overexpression. Mechanistically,
our genetic complementation data indicate that Arg2 cell
autonomously enhances hepatic insulin signaling in vitro and
in vivo and reduces hepatic fat accumulation via
Rgs16 suppression. The data give rise to the hypothesis that
Rgs16 suppresses hepatocyte-protective G-protein-coupled
receptor signaling events, the origin and nature of which
remain to be addressed.
RGS16 was previously identiﬁed as the only one of 21 RGS
genes that was regulated by circadian rhythms in the murine
suprachiasmatic nucleus and liver54,55. Hepatic Rgs16 was sub-
sequently determined to suppress hepatic fat oxidation by upre-
gulating the carbohydrate response element binding protein35.
Because the net physiological response to fasting in the liver is to
upregulate fat oxidation, the proposed Rgs16 function is to exert
negative feedback on Gi/Gq-mediated fat oxidation35,54. This
negative feedback appropriately moderates the prolonged fasting
response (e.g., during hibernation). In overfed contexts, in which
excess caloric and fat dissipation is an appropriate full-time
compensation, RGS16 function becomes maladaptive. The
maladaptive nature of this regulation is supported by comparing
Arg2 expression in db/db vs db/+ mice, HFrD-fed vs Chow-fed
mice and in primary hepatocyte cultures treated with or without
10 mM fructose. In each of these overfed contexts, Arg2 expres-
sion was suppressed. Our data demonstrating that Arg2 acts
upstream of Rgs16 to suppress its induction may reﬂect a mole-
cular bypass in this negative feedback loop. Clinically, this Arg2-
regulated bypass route may be exploited to treat NAFLD and
insulin resistance.
In summary, this report identiﬁes hepatic Arg2 suppression of
Rgs16 as a metabolic regulatory axis during fasting. Moreover, we
identify pharmacologic fasting mimetics—trehalose and lacto-
trehalose—which activate this axis analogous to physiological
fasting. Therefore, the hepatic intermediaries that mediate the
generalized macronutrient fasting response can be directly
leveraged to treat cardiometabolic disease.
Methods
Cell lines. AML12 cells (CRL-2254) were purchased directly from the American
Type Culture Collection (ATCC) and propagated and maintained precisely per
manufacturer speciﬁcation.
Primary hepatocyte cell isolation, culture and treatment. Primary murine
hepatocytes obtained from WT mice were isolated24,25,31 and cultured and
maintained in regular DMEM growth media (Sigma, #D5796) containing 10% FBS.
For in vitro starvation experiments, “starved” media contained 1 g/L glucose and
0.5% FBS was used. Cultures were lysed in Trizol and subjected to downstream
analysis. In vitro genetic knockdown was achieved via siRNA transfection using
Lipofectamine 3000 from Invitrogen (L3000015). Trehalose was obtained from
Sigma Aldrich (St. Louis, MO) and was >97% purity by HPLC. Three percent
trehalose water (w/v) fed ad libitum was used in all in vivo experiments.
In vitro insulin signaling. AML12 cells were seeded in 6-well plates. Cells were
infected with adenoviruses, Ad-GFP, or Ad-Arg2, for 24 h in regular DMEM
HAM/F12 growth media and starved in serum-free DMEM HAM/F12 media for
16 h before being treated with either serum-free media or serum-free media with
insulin (10 nM) for 10 min.
Animal studies. All animal protocols were approved by the Washington Uni-
versity School of Medicine Animal Studies Committee. Male C57B/6J mice and
db/db mice were purchased directly from the Jackson Laboratory (Bar Harbor, ME)
and housed a 12-h alternating light-dark, temperature-controlled, speciﬁc
pathogen-free barrier facility prior to and throughout experimentation.
All animals received humane care and procedures were performed in
accordance with the approved guidelines by the Animal Studies Committee at
Washington University School of Medicine. All animal studies were performed in
accordance with the criteria and ethical regulations outlined by the Institutional
Animal Care and Use Committee (IACUC).
Quantitative real-time RT-PCR (qRT-PCR). Total RNA was prepared by
homogenizing snap-frozen livers or cultured hepatocytes in Trizol reagent (Invi-
trogen #15596026) according to the manufacturer’s protocol. cDNA was prepared
using Qiagen Quantitect reverse transcriptase kit (Qiagen #205310). Real-time
qPCR was performed with Step-One Plus Real-Time PCR System (Applied Bio-
systems) using SYBR Green master Mix Reagent (Applied Biosystems) and speciﬁc
primer pairs. Relative gene expression was calculated by a comparative method
using values normalized to the expression of an internal control gene. Primers are
shown in Supplementary Table 2.
Immunoblotting. Tissues were homogenized in RIPA buffer supplemented with
protease and phosphatase inhibitors (Thermo Scientiﬁc). After homogenization,
lysate was centrifuged at 18,000 × g for 15 min at 4 °C, and the supernatant was
recovered. Protein concentration was determined by BCA Assay Kit (Thermo
Scientiﬁc) and was adjusted to 2 mg/mL. Samples for western blotting were pre-
pared by adding Laemmli buffer at a ratio of 1:1 and heating at 95 °C for 5 min.
The prepared samples were subjected to 10% or 13% SDS-PAGE, followed by
electrical transfer onto a nitrocellulose membrane using the Trans-Blot Turbo
system (Bio-Rad). After blocking the membrane with 5% milk in TBST, the
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membrane was incubated in primary antibody at 4 °C overnight. The blot was
developed after secondary antibody incubation using Pierce ECL Western Blotting
Substrate (Thermo Scientiﬁc). Blots were developed according to the manu-
facturer’s instructions. Protein expression levels were quantiﬁed with Image Lab
software and normalized to the levels of β-actin or GAPDH.
Antibodies. Antibodies against phosphor-IRS1 (Ser636/639) (no. 2388), IRS1 (no.
2382), phosphor-AKT (Ser473) (no. 9271), AKT (no. 9272), GAPDH (no. 5174),
and β-actin (no. 3700) were purchased from Cell Signaling Technology (CST)
(Beverly, MA, USA). Anti-Arg2 antibody was purchased from Santa Cruz Bio-
technology (no. Ab154422). Antibody against RGS16 (no. NBP2-01584) was
purchased from Novus Biologicals, LLC (no. Ab203071) (Littleton, CO, USA). The
dilution ratio for all primary antibodies was 1:1000. The secondary antibodies used
in this study were peroxidase-conjugated anti-rabbit IgG (A7074) and anti-mouse
IgG (A7076) purchased from CST, in which were used at a 1:5000 dilution.
Histological analysis. Formalin-ﬁxed parafﬁn-embedded liver sections were
stained by H&E via the Washington University Digestive Diseases Research Core
Center. OCT-embedded frozen liver sections were stained by Oil Red O according
to standard protocols ﬂowered by microscopic examination. Three liver sections
were examined and evaluated for each animal. For Oil red O staining, ice-cold
methanol-ﬁxed frozen sections from mice were stained according to described
protocols 24,25,31.
Lactotrehalose synthesis and puriﬁcation was carried out using
chemoenzymatic synthesis and puriﬁcation methods we described56. Reactions
were performed in 50 mM HEPES buffer (pH 7.4) containing 10 mM galactose,
40 mM UDP-glucose, 20 mM MgCl2, and 9.8 μM TreT at 70 °C. We conﬁrmed
98–99% purity by 1H-NMR (not shown). We conﬁrmed 98–99% purity by 1H-
NMR prior to experiments.
AAV8- and adenovirus-mediated overexpression. Serotype 8 AAV (AAV8) was
administered via tail vein as we previously reported29. All viral vectors (RGS16,
Arg2, shTFEB) were obtained directly from Vector Biolabs Inc (Philadelphia, PA).
Antisense oligonucleotides. We obtained validated Arg2-speciﬁc antisense oli-
gonucleotides from IONIS Pharmaceuticals (Carlsbad, CA). Mice were treated
precisely as we previously reported27,32, prior to in vivo and post-mortem assays.
Insulin and glucose tolerance testing. For insulin tolerance tests (ITT), mice
were injected with 0.75 IU per kg body weight of insulin (Humalog, Eli Lilly)
intraperitoneally after 4 h of fasting on Aspen bedding. For glucose tolerance tests
(GTT), mice were injected with 2 g per kg body weight of glucose intraperitoneally
after fasting for 4 h on aspen bedding. db/db mice were injected with 1 g per kg
body weight of glucose intraperitoneally after fasting for 16 h on aspen bedding.
Blood samples were measured at different time points with a glucometer (Arkray
USA, Inc., Minneapolis, MN, USA).
Clinical chemistry measurements and hepatic lipid analyses. For all other
serum analyses, submandibular blood collection was performed immediately prior
to sacriﬁce and serum was separated. Insulin ELISA (Millipore #EZRMI-13K),
triglycerides (Thermo Fisher Scientiﬁc #TR22421), cholesterol (Thermo Fisher
Scientiﬁc #TR13421), and free fatty acids (Wako Diagnostics #999-34691, #995-
34791, #991-34891, #993-35191) quantiﬁcation were performed using commer-
cially available reagents according to manufacturer’s directions. Albumin levels
were quantiﬁed using an AMS LIASYS Chemistry Analyzer.
Hepatic lipids were extracted from ~100 mg hepatic tissue homogenized in 2:1
chloroform:methanol. In total, 0.25–0.5% of each extract was evaporated overnight
prior to biochemical quantiﬁcation of triglycerides, LDL-C, cholesterol, and free
fatty acids using reagents described above, precisely according to manufacturer’s
directions.
Body composition analysis. Body composition analysis was carried out in una-
nesthetized mice using an EchoMRI 3-1 device (Echo Medical Systems) via the
Washington University Diabetic Mouse Models Phenotyping Core Facility.
Indirect calorimetry and food intake measurement. All measurements were
performed in a PhenoMaster System (TSE systems) via the Washington University
Diabetic Mouse Models Phenotyping Core Facility, which allowed metabolic per-
formance measurement and activity monitoring by an infrared light= beam frame.
Mice were placed at room temperature (22–24 °C) in separate chambers of the
PhenoMaster open-circuit calorimetry. Mice were allowed to acclimatize in the
chambers for 4 h. Food and water were provided ad libitum in the appropriate
devices. The parameters of indirect calorimetry (VO2, VCO2, respiratory exchange
ratio (RER), heat and movement) were measured for at least 24 h for a minimum of
one light cycle (6:01 am to 6:00 pm) and one dark cycle (6:01 pm to 6:00 am).
Presented data are average values obtained in these recordings.
RNA-seq. RNA-seq was performed by the Washington University Genome
Technology Access Center (GTAC). Library preparation was performed with 10 µg
of total RNA with a Bioanalyzer RIN score greater than 8.0. Ribosomal RNA was
removed by poly-A selection using Oligo-dT beads (mRNA Direct kit, Life
Technologies). mRNA was then fragmented in buffer containing 40 mM Tris
acetate pH 8.2, 100 mM potassium acetate and 30 mM magnesium acetate and
heating to 94 °C for 150 s. mRNA was reverse transcribed to yield cNDA using
SuperScript III RT enzyme (Life Technologies, per manufacturer’s instructions)
and random hexamers. A second strand reaction was performed to yield ds-cDNA.
cDNA was blunt ended, had an A base added to the 3′ ends, and then had Illumina
sequencing adapters ligated to the ends. Ligated fragments were then ampliﬁed for
12 cycles using primers incorporating unique index tags. Fragments were
sequenced on an Illumina HiSeq-3000 using single reads extending 50 bases.
RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with
STAR version 2.0.4b. Gene counts were derived from the number of uniquely
aligned unambiguous reads by Subread:featureCount version 1.4.5. Transcript
counts were produced by Sailﬁsh version 0.6.3. Sequencing performance was
assessed for total number of aligned reads, total number of uniquely aligned reads,
genes and transcripts detected, ribosomal fraction known junction saturation and
read distribution over known gene models with RSeQC version 2.3.
To enhance the biological interpretation of the large set of transcripts, grouping of
genes/transcripts based on functional similarity was achieved using the R/Bioconductor
packages GAGE and Pathview. GAGE and Pathview were also used to generate
pathway maps on known signaling and metabolism pathways curated by KEGG.
Targeted metabolomics. We performed targeted metabolomics as reported with
minor modiﬁcations57. Brieﬂy, the liver samples were homogenized in water
(4 mL/g liver). The amino acids in 20 µL of mouse serum or liver homogenate were
extracted with protein precipitation in the presence of internal standards
(13C6,15N-Ile, d3-Leu, d8-Lys, d8-Phe, d8-Trp, d4-Tyr, d8-Val, d7-Pro, 13C4-Thr,
d3-Met, d2-Gly, d3,15N2-Asn, d4-Cit, d3-Asp, 13C5-Gln, 13C6-His, d3-Glu, d4-
Ala, d3-Ser, 13C5-Orn, and 13C6-Arg). Quality control (QC) samples for livers
and sera were prepared from pooled partial study samples and injected every ﬁve
study samples to monitor intra-batch precision. Only the lipid species with CV% <
15% for QC injections are reported. The Ile, Leu, Lys, Phe, Trp, Tyr, Val, Pro, Thr,
Met, Gly, Asn, Cit, Asp, Gln, His, Glu, Ala, Ser, Orn, and Arg were analyzed on
4000 QTRAP mass spectrometer coupled with a Prominence LC-20AD HPLC
system. Data processing was conducted with Analyst 1.5.1 (Applied Biosystems).
Statistical analyses. Data were analyzed using GraphPad Prism version 6.0 (RRID:
SCR_015807). p < 0.05 was deﬁned as statistically signiﬁcant. Data shown are as
mean ± SEM. In box-whisker plots: middle bar represents the dataset median; boxes
represent 25 and 75 percentile lines; whiskers represent maximum and minimum
values in the dataset. In dot plots: the line represents the data mean. Unpaired two-
tailed homoscedastic T-tests with Bonferroni post hoc correction for multiple
comparisons were used for all analyses unless otherwise noted in the ﬁgure legends.
Two-way ANOVA was also used for analyses with two independent variables.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
There are no restrictions on data or material availability. The data that support the
ﬁndings of this study are available from the authors on reasonable request. Raw RNA
sequencing data ﬁles have been deposited into the Gene Expression Omnibus database
(www.ncbi.nlm.nih.gov/geo/) with accession number GSE126134.
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